182 related articles for article (PubMed ID: 35534342)
1. The AGH score is a predictor of disease-free survival and targeted therapy efficacy after liver transplantation in patients with hepatocellular carcinoma.
Li JH; Chen T; Xing H; Li RD; Shen CH; Zhang QB; Tao YF; Wang ZX
Hepatobiliary Pancreat Dis Int; 2023 Jun; 22(3):245-252. PubMed ID: 35534342
[TBL] [Abstract][Full Text] [Related]
2. Homocysteine: A novel prognostic biomarker in liver transplantation for alpha-fetoprotein- negative hepatocellular carcinoma.
Yang M; Tan W; Yang X; Zhuo J; Lin Z; Cen B; Lian Z; Li H; Lu D; Wei X; Zheng S; Xu X
Cancer Biomark; 2020; 29(2):197-206. PubMed ID: 32623388
[TBL] [Abstract][Full Text] [Related]
3. Clinical outcome in patients with hepatocellular carcinoma after living-donor liver transplantation.
Choi HJ; Kim DG; Na GH; Han JH; Hong TH; You YK
World J Gastroenterol; 2013 Aug; 19(29):4737-44. PubMed ID: 23922471
[TBL] [Abstract][Full Text] [Related]
4. A novel prognostic nomogram accurately predicts hepatocellular carcinoma recurrence after liver transplantation: analysis of 865 consecutive liver transplant recipients.
Agopian VG; Harlander-Locke M; Zarrinpar A; Kaldas FM; Farmer DG; Yersiz H; Finn RS; Tong M; Hiatt JR; Busuttil RW
J Am Coll Surg; 2015 Apr; 220(4):416-27. PubMed ID: 25690672
[TBL] [Abstract][Full Text] [Related]
5. Alpha-fetoprotein level > 1000 ng/mL as an exclusion criterion for liver transplantation in patients with hepatocellular carcinoma meeting the Milan criteria.
Hameed B; Mehta N; Sapisochin G; Roberts JP; Yao FY
Liver Transpl; 2014 Aug; 20(8):945-51. PubMed ID: 24797281
[TBL] [Abstract][Full Text] [Related]
6. Validation of the AFP model as a predictor of HCC recurrence in patients with viral hepatitis-related cirrhosis who had received a liver transplant for HCC.
Notarpaolo A; Layese R; Magistri P; Gambato M; Colledan M; Magini G; Miglioresi L; Vitale A; Vennarecci G; Ambrosio CD; Burra P; Di Benedetto F; Fagiuoli S; Colasanti M; Maria Ettorre G; Andreoli A; Cillo U; Laurent A; Katsahian S; Audureau E; Roudot-Thoraval F; Duvoux C
J Hepatol; 2017 Mar; 66(3):552-559. PubMed ID: 27899297
[TBL] [Abstract][Full Text] [Related]
7. The ratio of preoperative alpha-fetoprotein level to total tumor volume as a prognostic factor of hepatocellular carcinoma after liver transplantation.
Jiang T; Zhang XS; Pan F; Lyu SC; Wang J; Huang MX; He Q; Lang R
Medicine (Baltimore); 2021 Jul; 100(26):e26487. PubMed ID: 34190174
[TBL] [Abstract][Full Text] [Related]
8. Role of selected criteria and preventive chemotherapy in tumor recurrence after liver transplantation.
Wang MX; Chen D; Zhao YY; Yang B; Jiang JP; Zeng FJ; Wei L; Chen ZS
Hepatobiliary Pancreat Dis Int; 2020 Aug; 19(4):378-383. PubMed ID: 32622825
[TBL] [Abstract][Full Text] [Related]
9. Serological Risk Index Based on Alpha-Fetoprotein and C-Reactive Protein to Indicate Futile Liver Transplantation Among Patients with Advanced Hepatocellular Carcinoma.
Kornberg A; Schernhammer M; Kornberg J; Friess H; Thrum K
Dig Dis Sci; 2019 Jan; 64(1):269-280. PubMed ID: 30259282
[TBL] [Abstract][Full Text] [Related]
10. Rate of tumor growth predicts recurrence of hepatocellular carcinoma after liver transplantation in patients beyond Milan or UCSF criteria.
Hanouneh IA; Macaron C; Lopez R; Aucejo F; Zein NN
Transplant Proc; 2011 Dec; 43(10):3813-8. PubMed ID: 22172852
[TBL] [Abstract][Full Text] [Related]
11. Time of hepatocellular carcinoma recurrence after liver resection and alpha-fetoprotein are important prognostic factors for salvage liver transplantation.
Lee S; Hyuck David Kwon C; Man Kim J; Joh JW; Woon Paik S; Kim BW; Wang HJ; Lee KW; Suh KS; Lee SK
Liver Transpl; 2014 Sep; 20(9):1057-63. PubMed ID: 24862741
[TBL] [Abstract][Full Text] [Related]
12. Liver transplantation for hepatocellular carcinoma: Hangzhou experiences.
Zheng SS; Xu X; Wu J; Chen J; Wang WL; Zhang M; Liang TB; Wu LM
Transplantation; 2008 Jun; 85(12):1726-32. PubMed ID: 18580463
[TBL] [Abstract][Full Text] [Related]
13. Alpha-fetoprotein-adjusted-to-HCC-size criteria are associated with favourable survival after liver transplantation for hepatocellular carcinoma.
Meischl T; Rasoul-Rockenschaub S; Győri G; Scheiner B; Trauner M; Soliman T; Berlakovich G; Pinter M
United European Gastroenterol J; 2021 Mar; 9(2):209-219. PubMed ID: 32741316
[TBL] [Abstract][Full Text] [Related]
14. Alpha-Fetoprotein Slope >7.5 ng/mL per Month Predicts Microvascular Invasion and Tumor Recurrence After Liver Transplantation for Hepatocellular Carcinoma.
Giard JM; Mehta N; Dodge JL; Roberts JP; Yao FY
Transplantation; 2018 May; 102(5):816-822. PubMed ID: 29505494
[TBL] [Abstract][Full Text] [Related]
15. Histological differentiation predicts post-liver transplantation survival time.
Li WX; Li Z; Gao PJ; Gao J; Zhu JY
Clin Res Hepatol Gastroenterol; 2014 Apr; 38(2):201-8. PubMed ID: 24388339
[TBL] [Abstract][Full Text] [Related]
16. Development of a Risk Classifier to Predict Tumor Recurrence and Lenvatinib Benefits in Hepatocellular Carcinoma After Liver Transplantation.
Deng Y; Yang J; Chen Y; Wang J; Fu B; Zhang T; Yi S; Yang Y
Transplant Proc; 2023; 55(1):153-163. PubMed ID: 36522222
[TBL] [Abstract][Full Text] [Related]
17. Combined Hangzhou criteria with neutrophil-lymphocyte ratio is superior to other criteria in selecting liver transplantation candidates with HBV-related hepatocellular carcinoma.
Xiao GQ; Yang JY; Yan LN
Hepatobiliary Pancreat Dis Int; 2015 Dec; 14(6):588-95. PubMed ID: 26663006
[TBL] [Abstract][Full Text] [Related]
18. Prediction of Early Recurrence of Hepatocellular Carcinoma in Patients with Cirrhosis Who Had Received Deceased Donor Liver Transplantation: A Multicenter Study.
Al-Ameri AAM; Wei X; Liu P; Lin L; Shao Z; Xie H; Zhou L; Zheng S; Xu X
Ann Transplant; 2019 Aug; 24():489-498. PubMed ID: 31427563
[TBL] [Abstract][Full Text] [Related]
19. Identifying patients at higher risk of hepatocellular carcinoma recurrence after liver transplantation in a multicenter cohort study from Argentina.
Piñero F; Marciano S; Anders M; Orozco Ganem F; Zerega A; Cagliani J; Andriani O; de Santibañes E; Gil O; Podestá LG; McCormack L; Gadano A; Silva M
Eur J Gastroenterol Hepatol; 2016 Apr; 28(4):421-7. PubMed ID: 26684693
[TBL] [Abstract][Full Text] [Related]
20. Validation of a Risk Estimation of Tumor Recurrence After Transplant (RETREAT) Score for Hepatocellular Carcinoma Recurrence After Liver Transplant.
Mehta N; Heimbach J; Harnois DM; Sapisochin G; Dodge JL; Lee D; Burns JM; Sanchez W; Greig PD; Grant DR; Roberts JP; Yao FY
JAMA Oncol; 2017 Apr; 3(4):493-500. PubMed ID: 27838698
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
